L3VLUP
ProSign in

LGND in the 13F filings

Ligand Pharmaceuticals Inc · CUSIP 53220K504

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 1 listed it in both
Shares listed
1,341,873
combined, among listed positions
Reported value
$80m
combined, at the quarter end

Managers listing LGND in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Janus Henderson Group Ltd1,341,873$80m0.05%Trimmed-2,68214 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q3 2024 to 5 in Q2 2026

Tracked managers listing it, at least.

0510152014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
LGND by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20131$506kn.a.n.a.
Q1 20141$3.2mn.a.n.a.
Q3 20141$9.1mn.a.n.a.
Q4 20141$5.1mn.a.n.a.
Q2 20152$2.8mn.a.n.a.
Q3 20152$2.2mn.a.n.a.
Q4 20151$5.9mn.a.n.a.
Q1 20161$7.5mn.a.n.a.
Q2 20163$26mn.a.n.a.
Q3 20162$1.2mn.a.n.a.
Q2 20171$72mn.a.n.a.
Q3 20172$105mn.a.n.a.
Q4 20171$125mn.a.n.a.
Q1 20189$289mn.a.n.a.
Q2 201810$400mn.a.n.a.
Q3 20188$544mn.a.n.a.
Q4 201811$513mn.a.n.a.
Q1 20197$438mn.a.n.a.
Q2 20197$397mn.a.n.a.
Q3 20195$315mn.a.n.a.
Q4 20198$371mn.a.n.a.
Q1 20209$195mn.a.n.a.
Q2 20205$221mn.a.n.a.
Q3 20204$189mn.a.n.a.
Q4 20202$169mn.a.n.a.
Q1 20212$204mn.a.n.a.
Q2 20211$189mn.a.n.a.
Q3 20211$204mn.a.n.a.
Q4 20211$223mn.a.n.a.
Q1 20221$156mn.a.n.a.
Q2 20221$124mn.a.n.a.
Q3 20221$109mn.a.n.a.
Q4 20221$84mn.a.n.a.
Q1 20231$93mn.a.n.a.
Q2 20231$97mn.a.n.a.
Q3 20231$80mn.a.n.a.
Q4 20232$97m20
Q1 20241$74m02
Q2 20241$85m10
Q3 20241$101m10
Q4 20241$109m10
Q1 20251$111m10
Q2 20251$121m10
Q3 20253$283m21
Q4 20253$287m1410
Q1 20263$288m168
Q2 20265$908m1212

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

LGND and LLY →LGND and JNJ →LGND and VRTX →Choose a stock to compare with LGND →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own LGND, latest filings →Back to the 13F Explorer →